Innovative biotechnologies: bacteriophages against infections

Pherecydes Pharma and BIOASTER join forces for the PhagUTI project


Romainville and Lyon, France, July 16, 2019

In order to explore the use of phage therapy to treat complicated urinary tract infections, Pherecydes Pharma and BIOASTER, the French Technology Research Institute (TRI) for Microbiology and Infectious Diseases, announced the signing of a collaboration agreement.


Sciences & Avenir returns about phagotherapy

Sciences & Avenir

In its June 2019 issue, Science et Avenir evokes the history of phagotherapy and the renewed interest of French research and ANSM for this promising alternative to antibiotic therapy.

In particular, the article mentions the ability of Pherecydes Pharma to produce high quality phages to enable precision therapy.


A new facility

Architecte : AIA LIFE DESIGNERS - Photos ©G.Satre

As part of the forthcoming installation of its bacteriophage GMP production site, Pherecydes Pharma opens a second facility in Nantes.

The facility is located 22 boulevard Benoni Goullin, in the Nantes Biotech business incubator on the Isle of Nantes.

Works, started in early September 2018, were completed at the end of March 2019.


Last ressort treatment against Staphylococcus aureus

Local administration of a phage anti-staphylococcal mixture associated to antibiotics prevented the removal of a hip prosthesis, which would have led to a loss of mobility of the patient's leg.

With 20 months of relapse-free recurrence today, this treatment of last resort is considered a success.


Guy-Charles Fanneau de La Horie

Antibiotic resistance is a major health challenge in the years to come: 10 million people may die in 2050. New approaches are needed; Phage therapy represents the most promising hope. Pherecydes Pharma makes every effort to provide physicians and patients with effective treatments for the most serious bacterial infections.

Guy-Charles Fanneau de La Horie, Chief Executive Officer at Pherecydes Pharma

Magali Vidal-Engaurran

Pherecydes Pharma's project is to develop and produce drugs containing phages to offer a therapeutic alternative to antibiotic resistance. This development of pharmaceutical products goes side by side with the transformation of the company to become a pharmaceutical laboratory through the setup of its manufacturing site in Nantes. Quality issues are therefore at the heart of the transformation of Pherecydes Pharma.

Magali Vidal-Engaurran, Senior Pharmacist


You can view all the information here

Pherecydes-Pharma is member of

Medicen Adebiotech Leem Beam Alliance Biocitech France Biotech